Shamburg News · 8-K filed Nov 12, 2026, 4:15 PM EST

BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

BLSM · BlossomHill Therapeutics, Inc.

  • Earnings
  • Financial statements
  • Materiality: high

BlossomHill Therapeutics reported a third-quarter 2026 net loss of $24.0 million, or $(1.29) per basic and diluted share, compared with $16.0 million, or $(6.54) per share, a year earlier. R&D expenses were $21.9 million and G&A expenses were $3.6 million for the quarter. The company reported $224.9 million in cash and cash equivalents as of September 30, 2026, and said it expects that balance to fund operations into the second quarter of 2028.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-458447.

Written from the filing by Shamburg Markets. Figures are as reported by the company.